Analysts split on Biogen's potential sale

11/14/2007 | Boston Globe (tiered subscription model), The

A biotech analyst said the potential sale of Biogen Idec to a major drugmaker could reach up to $30 billion if buyers remain positive on the future of its multiple sclerosis drug Tysabri in the market. However, some stock analysts believe the company might not be able to find a buyer due to competition and Biogen's drug-development deals with Elan Corp. and Genentech.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA